Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic, T-Cell 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 22fludarabine 20venetoclax 8Whole-Body Irradiation 8Mycophenolic Acid 8Standard of Care 6Mesna 6Melphalan 6Azacitidine 6fludarabine phosphate 5Sirolimus 5thymoglobulin 4Thiotepa 4Tacrolimus 4Specimen Handling 4Filgrastim 4Cytarabine 4entrectinib 3daratumumab 3cobimetinib 3alectinib 3Vemurafenib 3Surveys and Questionnaires 3Rituximab 3Practice Guidelines as Topic 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Busulfan 3Bortezomib 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hematologic Neoplasms × Lisaftoclax × Clear all
NCT03537482 2024-08-19

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Ascentage Pharma Group Inc.

Phase EARLY_PHASE1 Recruiting
90 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡